NR 293 Edapt

Student Name

Chamberlain University

NR-293: Pharmacology for Nursing Practice

Prof. Name

Date

Week 3: Gas Exchange and Bronchodilators

Introduction to Bronchodilators

Optimal gas exchange begins with a thorough respiratory assessment, enabling the nurse to prioritize interventions appropriately. Bronchodilators play a central role in pharmacotherapeutic strategies for respiratory conditions. These medications enhance breathing by widening the airways, easing mucus clearance, and minimizing inflammation. Depending on the formulation, they may act as single agents or as part of combination therapies with synergistic effects. Administration order is also significant—some drugs are taken first to open airways, improving the effectiveness of subsequent medications.

Conditions Managed with Respiratory Medications

Respiratory medications are prescribed to address a range of acute and chronic conditions, such as:

• Seasonal allergies and hay fever
• Asthma
• Chronic obstructive pulmonary disease (COPD)
• Emphysema
• Chronic bronchitis

These medications can target inflammation, relax smooth muscles, reduce secretions, and control allergic responses.

Rescue Inhalers and Drug Classifications

Short-acting inhaled beta2-adrenergic agonists are recommended as “rescue” inhalers to relieve sudden episodes of breathlessness rather than for daily maintenance. In clinical practice, respiratory drugs are categorized according to their primary therapeutic effect.

Classification	Examples	Primary Uses
Bronchodilators	Albuterol, Levalbuterol	Relief of asthma and COPD symptoms
Antihistamines	Loratadine, Fexofenadine	Management of allergic rhinitis, anaphylaxis
Expectorants	Guaifenesin	Loosening and clearance of mucus
Antitussives	Codeine, Dextromethorphan	Suppressing persistent cough
Decongestants	Fluticasone, Triamcinolone	Reducing nasal congestion

Use of Respiratory Medications

Respiratory medications are essential in controlling airway inflammation, alleviating bronchospasm, and improving ventilation. In emergency situations, adrenergic agents may be administered to stimulate cardiac output and rapidly dilate airways, enhancing oxygenation.

Types of Bronchodilators

Antihistamines

These medications block histamine activity, constrict smooth muscle in nasal passages, decrease secretions, and reduce capillary permeability. They are highly effective in allergic rhinitis and anaphylaxis.

Decongestants

Decongestants may be adrenergic, anticholinergic, or corticosteroid-based. They shrink swollen nasal tissues, improving airflow and easing congestion.

Antitussives

These agents suppress cough by acting on the brain’s cough center, reducing the urge to cough.

Expectorants

Expectorants help thin mucus, making it easier to expel from the respiratory tract.

Short-Acting Beta-Adrenergic Agonists (SABA)

SABAs, such as albuterol, are essential in acute asthma management, providing rapid relief by relaxing bronchial smooth muscle. For example, Valine, a 24-year-old nursing student with newly diagnosed asthma, experiences post-exertional shortness of breath and chest tightness; in such cases, an inhaled SABA offers quick symptom relief.

Long-Acting Beta2 Agonists (LABA)

LABAs, including salmeterol and formoterol, are intended for long-term symptom control in asthma and COPD, not for acute episodes. They are commonly combined with inhaled corticosteroids and typically administered twice daily.

Anticholinergics

Ipratropium is the most commonly used anticholinergic bronchodilator. By blocking acetylcholine in airway smooth muscle, it prevents bronchoconstriction and facilitates airflow, particularly in COPD, chronic bronchitis, and emphysema.

Contraindications for Ipratropium:

Condition	Reason for Avoidance
Glaucoma	May worsen intraocular pressure
Enlarged prostate	Can aggravate urinary retention
Urinary retention disorders	May exacerbate symptoms

Adverse Effects: Cough, nervousness, nausea, xerostomia, headache, and, rarely, paradoxical bronchospasm or anaphylaxis.

Drug Interactions with Ipratropium

Only one direct drug contraindication exists—revefenacin. Caution is required when combined with other anticholinergics or drugs metabolized by the CYP450 system.

Condition	Potential Interacting Medications
Depression, anxiety	Antidepressants, anxiolytics
Seasonal allergies	Antihistamines
Parkinson’s disease	Anticholinergics
Gastrointestinal issues	Antacids, GI medications
Overactive bladder	Anticholinergics
Use of other bronchodilators	Additional respiratory agents

Dosage Information for Ipratropium

Parameter	Details
Typical dosage	0.25–0.5 mg per 2.5 mL
Renal/Hepatic adjustment	Not required
Use in asthma	For exacerbations only, not as rescue therapy
Compatibility	Can be nebulized with albuterol or levalbuterol within 1 hour of mixing

NR 293 Edapt

Key Patient Education Points:

• Not for individuals under 12 years old (Atrovent HFA not for under 18).
• Not a rescue inhaler; use SABAs for acute attacks.
• Avoid high heat; store at room temperature.
• If using a nebulizer, space doses 6–8 hours apart.
• Avoid eye contact—especially important for patients with glaucoma.

Albuterol: A Beta Agonist

Mechanism of Action: Stimulates beta-2 adrenergic receptors in bronchial smooth muscle, causing relaxation and bronchodilation.

Body System	Effect
Respiratory	Bronchodilation
Cardiovascular	Mild vasoconstriction, possible increased heart rate

Contraindications: Allergy to albuterol, uncontrolled cardiovascular disease.
Adverse Effects: Tachycardia, chest discomfort, dizziness, nervousness, headache.

Dosage Form	Max Daily Dose (Adults)	Max Daily Dose (Pediatrics)
Inhalation/Oral	32 mg	12 mg

Patient Education:

• Supervise children during use.
• Administer 15–30 min before exercise to prevent bronchospasm.
• Avoid if allergic to milk proteins (ProAir RespiClick).

Theophylline: Overview

Acts as a CNS stimulant and bronchodilator, metabolizing into caffeine. Increases respiratory rate and enhances cardiac output, but requires careful dosing due to a narrow therapeutic range.

Therapeutic Range	mcg/mL
Standard	10–20
Preferred by clinicians	5–15
Toxicity likely	>20

Key Caution: Smoking accelerates metabolism, lowering drug levels. Dose adjustments may be needed for smokers or those who recently quit.

Preventive Asthma Medications

Used for long-term control, not acute relief. May include monoclonal antibodies (e.g., omalizumab, mepolizumab) and inhaled corticosteroids (e.g., fluticasone).

Medication	Action
Omalizumab	Binds IgE
Mepolizumab	Blocks IL-5 receptor (6+ years)
Benralizumab	Blocks IL-5 receptor (12+ years)

Inhaled Corticosteroids:

• Rinse mouth after use to prevent oral candidiasis.
• Avoid in severe milk protein allergy.

Montelukast (LTRA)

Blocks leukotrienes, reducing airway inflammation. Not for acute asthma attacks.

Indication	Adult Dose
Asthma/Allergic Rhinitis	10 mg daily
Exercise-Induced Bronchospasm	10 mg at least 2 hrs before exercise

Monitoring: Check liver enzymes (ALT, AST) during therapy.

Nursing Interventions

Intervention	Key Details
Inhaler technique	Demonstrate and observe patient return-demonstration
Dose adherence	Prevent under- or overdosing
MDI coordination	Wait 1–2 min between puffs of same drug; 2–5 min between different inhalers
Spacer use	Improves delivery efficiency

Evaluation of Medication Effectiveness

• Clear airway
• Reduced congestion
• Improved oxygenation
• Patient demonstrates understanding and correct self-care techniques

Documentation Guidelines

• Respiratory assessment findings
• Medication response and side effects
• Device use and care plan updates

Antihistamines Overview

Block H1 receptors to reduce allergic responses. Effective for rhinitis, urticaria, and anaphylaxis.

Adverse Effects: Drowsiness, dry mouth, constipation, urinary retention.

Conclusion

A comprehensive understanding of bronchodilators, corticosteroids, LTRAs, and adjunct therapies enables healthcare providers to tailor treatment to each patient’s needs. Effective education, proper inhaler technique, and close monitoring ensure safety and optimize respiratory health.

References

American Thoracic Society. (2021). Guidelines for the management of asthma. https://www.thoracic.org

Dhingra, N. (2020). Pharmacotherapy for respiratory disorders. Journal of Clinical Pharmacy, 45(2), 150–162.

NR 293 Edapt

MedlinePlus. (2022). Antihistamines. https://medlineplus.gov

National Heart, Lung, and Blood Institute. (2023). Asthma medications. https://www.nhlbi.nih.gov

U.S. Food and Drug Administration. (2021). Ipratropium bromide inhalation solution. https://www.fda.gov

U.S. National Library of Medicine. (2022). Albuterol. https://medlineplus.go